[ad_1] When most analysts are sounding praises for the pharma sector, Dharmesh Kant, Head – Equity & Derivative Research, Chola Securities, believes that it is the one sector that investors…
[ad_1] When most analysts are sounding praises for the pharma sector, Dharmesh Kant, Head – Equity & Derivative Research, Chola Securities, believes that it is the one sector that investors…